J. Sinisalo, E. Vlachopoulou, M. Marchesani, J. Nokelainen, M. Mäyränpää, J. Lappalainen, R. Paakkanen, A. Wennerström, K. Salli, H. J. Niemi, S. Männistö, P. Salo, J. Junttila, M. Eskola, K. Nikus, T. Arstila, M. Perola, H. Huikuri, P. Karhunen, P. Kovanen, A. Palotie, A. Havulinna, C. Lluís-Ganella, J. Marrugat, R. Elosúa, V. Salomaa, M. Nieminen, M. Lokki
{"title":"新的6p21.3风险单倍型易患急性冠状动脉综合征","authors":"J. Sinisalo, E. Vlachopoulou, M. Marchesani, J. Nokelainen, M. Mäyränpää, J. Lappalainen, R. Paakkanen, A. Wennerström, K. Salli, H. J. Niemi, S. Männistö, P. Salo, J. Junttila, M. Eskola, K. Nikus, T. Arstila, M. Perola, H. Huikuri, P. Karhunen, P. Kovanen, A. Palotie, A. Havulinna, C. Lluís-Ganella, J. Marrugat, R. Elosúa, V. Salomaa, M. Nieminen, M. Lokki","doi":"10.1161/CIRCGENETICS.115.001226","DOIUrl":null,"url":null,"abstract":"Background—The HLA-DRB1*01 allele of the human leukocyte antigen has been associated with acute coronary syndrome. Genome-wide association studies have revealed associations with human leukocyte antigen and non–human leukocyte antigen genes of 3 major histocompatibility complex gene classes but not at allelic level. Methods and Results—We conducted a large-scale genetic analysis on a case–control cohort comprising 5376 acute coronary syndrome cases and 4852 unrelated controls from 4 populations of 2 European countries. We analyzed the risk candidate allele of HLA-DRB1*01 by genomic real-time polymerase chain reaction together with high-density single nucleotide polymorphisms of the major histocompatibility complex to precisely identify risk loci for acute coronary syndrome with effective clinical implications. We found a risk haplotype for the disease containing single nucleotide polymorphisms from BTNL2 and HLA-DRA genes and the HLA-DRB1*01 allele. The association of the haplotype appeared in 3 of the 4 populations, and the direction of the effect was consistent in the fourth. Coronary samples from subjects homozygous for the disease-associated haplotype showed higher BTNL2 mRNA levels (r=0.760; P<0.00001).We localized, with immunofluorescence staining, BTNL2 in CD68-positive macrophages of the coronary artery plaques. In homozygous cases, BTNL2 blocking, in T-cell stimulation assays, enhanced CD4+FOXP3+ regulatory T cell proliferation significantly (blocking versus nonblocking; P<0.05). Conclusions—In cases with the risk haplotype for acute coronary syndrome, these results suggest involvement of enhanced immune reactions. BTNL2 may have an inhibitory effect on FOXP3+ T cell proliferation, especially in patients homozygous for the risk alleles. Clinical Trial Registration—https://www.clinicaltrials.gov; Unique Identifier: NCT00417534.","PeriodicalId":48940,"journal":{"name":"Circulation-Cardiovascular Genetics","volume":"9 1","pages":"55–63"},"PeriodicalIF":0.0000,"publicationDate":"2016-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1161/CIRCGENETICS.115.001226","citationCount":"8","resultStr":"{\"title\":\"Novel 6p21.3 Risk Haplotype Predisposes to Acute Coronary Syndrome\",\"authors\":\"J. Sinisalo, E. Vlachopoulou, M. Marchesani, J. Nokelainen, M. Mäyränpää, J. Lappalainen, R. Paakkanen, A. Wennerström, K. Salli, H. J. Niemi, S. Männistö, P. Salo, J. Junttila, M. Eskola, K. Nikus, T. Arstila, M. Perola, H. Huikuri, P. Karhunen, P. Kovanen, A. Palotie, A. Havulinna, C. Lluís-Ganella, J. Marrugat, R. Elosúa, V. Salomaa, M. Nieminen, M. Lokki\",\"doi\":\"10.1161/CIRCGENETICS.115.001226\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background—The HLA-DRB1*01 allele of the human leukocyte antigen has been associated with acute coronary syndrome. Genome-wide association studies have revealed associations with human leukocyte antigen and non–human leukocyte antigen genes of 3 major histocompatibility complex gene classes but not at allelic level. Methods and Results—We conducted a large-scale genetic analysis on a case–control cohort comprising 5376 acute coronary syndrome cases and 4852 unrelated controls from 4 populations of 2 European countries. We analyzed the risk candidate allele of HLA-DRB1*01 by genomic real-time polymerase chain reaction together with high-density single nucleotide polymorphisms of the major histocompatibility complex to precisely identify risk loci for acute coronary syndrome with effective clinical implications. We found a risk haplotype for the disease containing single nucleotide polymorphisms from BTNL2 and HLA-DRA genes and the HLA-DRB1*01 allele. The association of the haplotype appeared in 3 of the 4 populations, and the direction of the effect was consistent in the fourth. Coronary samples from subjects homozygous for the disease-associated haplotype showed higher BTNL2 mRNA levels (r=0.760; P<0.00001).We localized, with immunofluorescence staining, BTNL2 in CD68-positive macrophages of the coronary artery plaques. In homozygous cases, BTNL2 blocking, in T-cell stimulation assays, enhanced CD4+FOXP3+ regulatory T cell proliferation significantly (blocking versus nonblocking; P<0.05). Conclusions—In cases with the risk haplotype for acute coronary syndrome, these results suggest involvement of enhanced immune reactions. BTNL2 may have an inhibitory effect on FOXP3+ T cell proliferation, especially in patients homozygous for the risk alleles. Clinical Trial Registration—https://www.clinicaltrials.gov; Unique Identifier: NCT00417534.\",\"PeriodicalId\":48940,\"journal\":{\"name\":\"Circulation-Cardiovascular Genetics\",\"volume\":\"9 1\",\"pages\":\"55–63\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1161/CIRCGENETICS.115.001226\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Circulation-Cardiovascular Genetics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1161/CIRCGENETICS.115.001226\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation-Cardiovascular Genetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/CIRCGENETICS.115.001226","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
Novel 6p21.3 Risk Haplotype Predisposes to Acute Coronary Syndrome
Background—The HLA-DRB1*01 allele of the human leukocyte antigen has been associated with acute coronary syndrome. Genome-wide association studies have revealed associations with human leukocyte antigen and non–human leukocyte antigen genes of 3 major histocompatibility complex gene classes but not at allelic level. Methods and Results—We conducted a large-scale genetic analysis on a case–control cohort comprising 5376 acute coronary syndrome cases and 4852 unrelated controls from 4 populations of 2 European countries. We analyzed the risk candidate allele of HLA-DRB1*01 by genomic real-time polymerase chain reaction together with high-density single nucleotide polymorphisms of the major histocompatibility complex to precisely identify risk loci for acute coronary syndrome with effective clinical implications. We found a risk haplotype for the disease containing single nucleotide polymorphisms from BTNL2 and HLA-DRA genes and the HLA-DRB1*01 allele. The association of the haplotype appeared in 3 of the 4 populations, and the direction of the effect was consistent in the fourth. Coronary samples from subjects homozygous for the disease-associated haplotype showed higher BTNL2 mRNA levels (r=0.760; P<0.00001).We localized, with immunofluorescence staining, BTNL2 in CD68-positive macrophages of the coronary artery plaques. In homozygous cases, BTNL2 blocking, in T-cell stimulation assays, enhanced CD4+FOXP3+ regulatory T cell proliferation significantly (blocking versus nonblocking; P<0.05). Conclusions—In cases with the risk haplotype for acute coronary syndrome, these results suggest involvement of enhanced immune reactions. BTNL2 may have an inhibitory effect on FOXP3+ T cell proliferation, especially in patients homozygous for the risk alleles. Clinical Trial Registration—https://www.clinicaltrials.gov; Unique Identifier: NCT00417534.
期刊介绍:
Circulation: Genomic and Precision Medicine considers all types of original research articles, including studies conducted in human subjects, laboratory animals, in vitro, and in silico. Articles may include investigations of: clinical genetics as applied to the diagnosis and management of monogenic or oligogenic cardiovascular disorders; the molecular basis of complex cardiovascular disorders, including genome-wide association studies, exome and genome sequencing-based association studies, coding variant association studies, genetic linkage studies, epigenomics, transcriptomics, proteomics, metabolomics, and metagenomics; integration of electronic health record data or patient-generated data with any of the aforementioned approaches, including phenome-wide association studies, or with environmental or lifestyle factors; pharmacogenomics; regulation of gene expression; gene therapy and therapeutic genomic editing; systems biology approaches to the diagnosis and management of cardiovascular disorders; novel methods to perform any of the aforementioned studies; and novel applications of precision medicine. Above all, we seek studies with relevance to human cardiovascular biology and disease. Manuscripts are examined by the editorial staff and usually evaluated by expert reviewers assigned by the editors. Both clinical and basic articles will also be subject to statistical review, when appropriate. Provisional or final acceptance is based on originality, scientific content, and topical balance of the journal. Decisions are communicated by email, generally within six weeks. The editors will not discuss a decision about a manuscript over the phone. All rebuttals must be submitted in writing to the editorial office.